PR Newswire BiotechOriginal article
Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical
Phase 2positiveGV101Positive
AI Analysis
Summary
Graviton BioScience announced positive Phase 1b trial results for GV101, a selective ROCK2 inhibitor, showing 86.2% best overall response rate at 400 mg in chronic graft versus host disease patients with prior treatment failure. Results were published in Signal Transduction and Targeted Therapy.
Clinical Trial Data
Phase
1b
Primary Endpoint
Met
Outcome Details
86.2% best overall response rate (bORR) at 400 mg and 67.9% bORR at 200 mg at 24 weeks in cGvHD patients who had failed at least two prior lines of therapy
Importance:6/10
Sentiment:
0.85
clinical_trialphase_1bROCK2_inhibitorgraft_versus_host_diseasepublication
Read the original article
Published by PR Newswire Biotech on August 26, 2026 2:49 PM